➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Medtronic
Moodys
AstraZeneca

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

TRIPTODUR KIT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Triptodur Kit, and what generic alternatives are available?

Triptodur Kit is a drug marketed by Arbor Pharms Llc and is included in one NDA. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

US ANDA Litigation and Generic Entry Outlook for Triptodur Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 29, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for TRIPTODUR KIT
International Patents:46
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
DailyMed Link:TRIPTODUR KIT at DailyMed
Drug patent expirations by year for TRIPTODUR KIT
Generic Entry Opportunity Date for TRIPTODUR KIT
Generic Entry Date for TRIPTODUR KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TRIPTODUR KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Arbor Pharms Llc TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Arbor Pharms Llc TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.